Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T14:31:07.991Z Has data issue: false hasContentIssue false
  • English
  • Français

Differential Response to Aminergic Stimuli and Biological Behavior of Growth Hormone Secreting Pituitary Adenomas

Published online by Cambridge University Press:  18 September 2015

Guillermo Fanghanel ,
Oscar Larraza ,
Martha Villalobos ,
Leticia Fanghanel ,
Marcos Velasco  and
Francisco Velasco
Guillermo Fanghanel
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
Oscar Larraza
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
Martha Villalobos
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
Leticia Fanghanel
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
Marcos Velasco
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
Francisco Velasco*
Affiliation:
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, S.S., and Division of Neurophysiology, Scientific Research Department, IMSS Mexico, D.F. Mexico
*
Division of Neurophysiology, Scientific Research Dept., National Medical Centre, IMSS, P.O. Box 73-032, Mexico, D.F. Mexico
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Growth hormone (GH) serum levels in response to the administration of aminergic drugs and thyroliberine (TRH) were determined in a group of 34 acromegalics. Administration of bromocriptine (10 mg single oral dose) was followed by a decrease in GH below 60% control values in 35% of the cases. Administration of diazepam (10 mg single oral dose) to those cases not responding to bromocriptine induced a decrease in GH in 58% of the cases and an increase in GH in 42%. Administration of cyproheptadine (24 mg/day for one month) to those cases not responding to bromocriptine or with increased GH after the administration of diazepam, decreased GH in 75%, while increased GH in 25% of the cases. TRH 200 (Xg single I.V. dose induced increase of 128% GH basal level in 65% of cases (TRH positive) which correlated with more benign clinical course, decreased GH levels in response to bromocriptine, increased PRL levels, PRL-GH mixed secreting adenomas in immunohistochemistry studies, presence of granulated cells in electron microscopy studies and normalization of GH in the majority of surgically treated cases. By contrast, TRH negative cells correlated with aggressive tumor growth, lack of response to bromocriptine, normal PRL levels, pure GH secreting adenomas by immunohistochemistry, poorly granulated cells and lack of response to surgical treatment. Results suggest that there is more than one type of acromegaly that might be distinguished by the aminergic control on GH secretion.

Type
Special Supplement - Secreting Pituitary Adenomas
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 1 , February 1990 , pp. 78 - 82
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1.Brazeau, P, Vale, W, Burgus, R, et al. Hypothalamic peptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–81.CrossRefGoogle ScholarPubMed
2.Siler, TM, Vanderberg, G, Yen, SS, et al. Inhibition of growth hormone release in humans by somatostatin. J Clin Endocrinol Metab 1973; 37: 632–636.Google ScholarPubMed
3.Schally, AV, Baba, Y, Nair, RMG, et al. The amino-acid sequence of a peptide with growth hormone releasing activity isolated from porcine hypothalamus. J Biol Chem 1971; 246: 6647–6654.CrossRefGoogle ScholarPubMed
4.Guillemin, R, Brazeau, P, Ohlen, P, et al. Growth hormone-releasing factor from human pancreatic tumor that caused acromegaly. Science 1982; 218: 585–587.CrossRefGoogle ScholarPubMed
5.MacLeod, RM. Monoaminas hipotalámicas y secreción de hormonas hipofisiarias en condiciones normales y patológicas. En nuevos conceptos sobre fisiología y patología hipotálamohipofisiaria. (Valverde, C, Fanghanel, G, Mena, F, eds.) Conacyt Publicaciones. (México, D.F.) 1982; 103–134.Google Scholar
6.Russell, SM. Regulación de la secreción de la hormona de crecimiento. En nuevos conceptos sobre fisiología y patología hipotálamo-hipofisiaria. (Valverde, C, Fanghanel, G, Mena, F,eds.) Conacyt Publicaciones (México, D.F.) 1982; 219–242.Google Scholar
7.Fanghanel, G, Larraza, O, Arauco, E, et al. Serum growth hormone and ultrastructural study of adenohypophyseal tissue in bromocriptine treated acromegalic patients. Clin Endocrinol (OXF) 1978; 4: 289–295.CrossRefGoogle Scholar
8.Shibasaki, T, Hotta, M, Masuda, A. Studies on the response of growth hormone secretion to GH-releasing hormone, thyrotropin releasing hormone, gonadotropin-releasing hormone and somatostatin in acromegaly. J Clin Endocrinol Metab 1986; 63: 167–173.CrossRefGoogle ScholarPubMed
9.Thorner, MO, Chait, A, Aitken, M, et al. Bromocriptine treatment of acromegaly. Br Med J 1975; 1: 299–303.CrossRefGoogle ScholarPubMed
10.Teasdale, G. Bromocriptine in acromegaly. The Lancet 1976; 1:484–488.CrossRefGoogle ScholarPubMed
11.Hanew, K, Kokubon, M, Sasaki, A, et al. The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. J Clin Endocrinol Metab 1980; 51: 292–297.CrossRefGoogle ScholarPubMed
12.Pawlikowsky, M, Strejozek, K, Komorowski, J. Effects of thyroliber-ine (TRH), bromocriptine and cyproheptadine on somatotropin secretion in acromegaly. Materia Médica Polona 1980; 12: 7073.Google Scholar
13.Camanni, F, Molinatti, GM, Müller, EE. Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects. Neuroendocrinology 1975; 19: 227–231.CrossRefGoogle ScholarPubMed
14.Carimna, E, Lo Coco, R, Lanzara, P, et al. Effect of the acute admin-istration of bromocriptine, haloperidol and pimozide on plasma GH levels in acromegaly. Acta Endocrinol (Copenh) 1979; 91: 609–613.Google Scholar
15.Fedele, D, Molinar, M, Muggeo, M, et al. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients. J Endocrinol Invest 1980; 3: 149–153.CrossRefGoogle ScholarPubMed
16.Kannan, V. Diazepam test of growth hormone secretion. Hormone Metabolism Research 1981; 13: 390–393.CrossRefGoogle ScholarPubMed
17.Zaccaria, M, Giordano, G, Ragazzi, E. Lack of effect in diazepam administration on GH and PRL secretion in normal and acromegalic subjects. J Endocrinol Invest 1985; 8: 167–172.CrossRefGoogle Scholar
18.Nakai, Y, Imura, H, Sakurai, H. Effects of cyproheptadine in human growth hormone secretion. J Clin Endocrinol Metab 1974; 38: 446–449.CrossRefGoogle ScholarPubMed
19.Smythe, GA, Lazarus, L. Suppression of growth hormone secretion by malatonine and cyproheptadine. J Clin Invest 1974; 54: 116–119.CrossRefGoogle ScholarPubMed
20.Kovacs, K, Corenblum, B, Sirek, AM, et al. Ultrastructural morphometry in cell adenomas of human pituitary. J Clin Path 1976; 29: 250–255.CrossRefGoogle Scholar
21.Mc.Comb, DJ, Kovacs, K. Ultrastructural morphometry of sparsely granulated prolactin cell adenomas of the human pituitary. Acta Endocrinol (Copenh) 1978; 89: 521–526.Google ScholarPubMed
22.Vezina, JL, Nelson, B. Prolactin secreting pituitary microadenomas. Am J Radiol 1974; 120: 46–50.Google ScholarPubMed
23.Martínez-Campos, A, Cornejo, J, Garza Flores, J, et al. Dysfunction of dopaminergic regulation of prolactin in patients with functioning and non functioning pituitary adenomas and craneopharyn-geomas. Fertility and Sterility 1985; 44: 472–477.CrossRefGoogle Scholar
24.Cassar, J, Mashiter, K, Joplin, GF. Bromocriptine treatment of acromegaly. Metabolism 1977; 26: 539–545.CrossRefGoogle ScholarPubMed
25.Ajlouini, M. Failure of diazepam to affect growth hormone and prolactin in acromegalics. Horm Res 1983; 18: 186–190.Google Scholar
26.Velasco, F, Valasco, M, Jiménez, O, et al. Prognostic factors in the surgical treatment of hypophyseal adenomas. Arch Invest Med (Mex) 1985; 16: 59–73 (Suppl 3).Google ScholarPubMed
27.Müller, EE, Cavagnini, F, Martinez-Campos, A, et al. Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders. Acta Endocrinol (Copenh) 1984; 107: 155–159.Google ScholarPubMed
28.Larraza, O, Valverde, C, Fanghanel, G, et al. Morphofunctional correlative analysis of prolactin, growth hormone and thyrotropin secretion in pituitary neoplasia. In: Prolactin secretion. A multi-disciplinary approach. (Mena, F, Valverde, C, eds.) Academic Press 1983; 371–392.Google Scholar